Table 1.

Synthetic Peptides

Peptide	Sequence	I-TAC bindinga
	PT-gliadin	69
4012	MVRVPVPQLQPQNPSQQHPQ	98
4013	PQNPSQQHPQEQVPLVQQQQ	112
4014	EQVPLVQQQQFLGQQQSFPP	90
4015	FLGQQQSFPPQQPYPQPQPF	96
4016	QQPYPQPQPFPSQQPYLQLQ	103
4017	PSQQPYLQLQPFPQPQLPYL	94
4018	PFPQPQLPYLQPQPFRPQQP	93
4019	QPQPFRPQQPYPQPQPQYSQ	99
4020	YPQPQPQYSQPQQPISQQQQ	112
4021	PQQPISQQQQQQQQQQQQQQ	86
	QQQQQQQQQQQQQQQQQQQQ	—
4022	QQQQQQQQQQQQILQQILQQ	55
4023	QQILQQILQQQLIPCMDVVL	—
4024	QLIPCMDVVLQQHNIAHGRS	116
4025	QQHNIAHGRSQVLQQSTYQL	106
4026	QVLQQSTYQLLQELCCQHLW	36
4027	LQELCCQHLWQIPEQSQCQA	90
4028	QIPEQSQCQAIHNVVHAIIL	76
4029	IHNVVHAIILHQQQKQQQQP	93
4030	HQQQKQQQQPSSQVSFQQPL	126
4031	SSQVSFQQPLQQYPLGQGSF	100
4032	QQYPLGQGSFRPSQQNPLAQ	100
4033	RPSQQNPLAQGSVQPQQLPQ	108
4034	GSVQPQQLPQFEEIRNLALQ	95
4035	FEEIRNLALQTLPAMCNVYI	109
4036	TLPAMCNVYIPPYCTIVPFG	110
4037	PPYCTIVPFGIFGTNYR	108

NOTE. Designed peptides were subjected to a CXCR3 binding assay based on displacement of ^[125]-radiolabeled CXCR3 ligand I-TAC. In addition to PT-gliadin, 2 of the synthetic peptides were identified to bind to CXCR3 (depicted in bold).

^aPercentage binding average (n = 2).